Advanced or metastatic cancer of the breast or colon Part 1A: metastatic or advanced breast cancer or colorectal cancer for which no standard therapy is available Part 1B: metastatic or advanced breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting Part 1C: metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 1D: metastatic or advanced colorectal cancer without any prior chemotherapy for advanced or metastatic disease Part 2A: metastatic or advanced breast cancer with disease progression after at least 1 prior line of CDK4/6 inhibitor and at least 1 prior line of endocrine therapy Part 2B: metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2C: metastatic or advanced colorectal cancer without any prior chemotherapy for advanced or metastatic disease
Measurable disease
ECOG performance status 0 or 1
You may not be if
Active malignancy within 3 years prior to enrollment
Known symptomatic brain metastases requiring steroids
Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
Prior irradiation to \>25% of the bone marrow
Hypertension that cannot be controlled by optimal medical therapy
Renal impairment
Hepatic dysfunction
Cardiac abnormalities
Active bleeding disorder
Active or history of clinically significant GI disease
Other unacceptable abnormalities as defined by protocol
Clareo Health | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
